[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019-2023 Competing in the US Molecular Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

March 2019 | 1157 pages | ID: 20C8103DFA1EN
Venture Planning Group

US$ 8,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new 1157-page report from VPGMarketResearch contains 65 tables, and presents a comprehensive analysis of the US molecular diagnostics market, including:

Major issues pertaining to the US molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods.

Five-year test volume and reagent sales forecasts for the following categories:VPMD15074Review of testing methodologies an instrumentation technologies.

Feature comparison of automated and semiautomated analyzers.

Sales and market shares of leading suppliers.

Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products.

Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Business planning issues and concerns.
Contains 1,157 pages and 65 tables
I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies For Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge And Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. MARKET AND TECHNOLOGY REVIEW

A. DNA Sequencing
  1. Introduction
  2. Sequencing Methods
  3. Autoradiography
  4. The Human Genome Project
  5. Sequencing Automation
  6. Image Scanners
  7. Fluorescent Detection
  8. Gene Profiling
  9. Gene Expression
  10. Polymorphism Screening
  11. Protein Interaction Networks
B. DNA and RNA Probe Technologies
  1. Basic Principles
  2. Probe Preparation
  3. The DNA Probe Test
  4. Test Formats
  5. Labeling Techniques
  6. Amplification Methods
C. Detection Technologies
  1. Radioactive Methods
    a. Overview
    b. Major Isotopes
      P-32
      S-3
  6. bioMerieux NucliSENS easyMAG
  7. bioMerieux NucliSENS easyQ and MiniMAG
  8. Bio-Rad GeneScope
  9. Cepheid GeneXpert
  10. Curetis Unyvero
  11. GenMark Dx eSensor XT-8
  12. Hologic/Gen-Probe Panther
  13. Hologic/Gen-Probe Tigris/DTS
  14. HTG Molecular Edge
  15. Life Technologies QuantStudio Dx
  16. Qiagen QIAsymphony RGQ
  17. Roche Cobas Amplicor
  18. Roche Cobas TaqMan 48
  19. Roche Cobas TaqMan
  20. Roche Cobas TaqMan AmpliPrep
  21. Roche LighCycler 480
  22. Roche Cobas 4800
  23. Roche Cobas s 201
  24. Siemens Versant
  25. Tecan LS Series
E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
  Liquid Transportation and Mixing
  Separation
  Reaction
  Detection
F. Pharmacogenomics
G. Major Applications
  1. Microbiology/Infectious Diseases
    a. Overview
    b. Major Infectious Diseases
      AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
      Adenovirus
      Aeromonas
      Anthrax/Bacillus Anthracis
      Arboviruses
      Babesiosis
      Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
      Blastocystis Hominis
      Brucella
      Campylobacter
      Candida
      Chagas Disease
      Chancroid
      Chlamydia
      Clostridium Difficile
      Coronaviruses
      Coxsackieviruses
      Creutzfeldt-Jakob’s Disease
      Cryptosporidium Parvum
      Cyclospora Cayetanensis
      Cytomegalovirus
      Ebola Virus
      E. Coli
      EchoVirus
      Encephalitis
      Enteroviruses
      Epstein-Barr Virus
      Giardia Lamblia
      Gonorrhea
      Granuloma Inguinale
      Hantavirus
      Helicobacter Pylori
      Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
      Herpes Simplex Virus
      Human Herpes Virus-6 (HHV-6)
      Influenza Viruses
      Legionella
      Lyme Disease
      Lymphogranuloma Venereum (LGV)
      Malaria
      Measles (Rubeola)
      Meningitis
      Microsporidium
      Mononucleosis
      Mumps
      Mycoplasma
      Papillomaviruses
      Parvovirus B19
      Pneumonia
      Polyomaviruses
      Pseudomonas Aeruginosa
      Rabies
      Respiratory Syncytial Virus (RSV)
      Rhinoviruses
      Rotavirus
      Rubella
      Salmonellosis
      Septicemia
      Shigellosis
      Staphylococcus Aureus
      Streptococci
      Syphilis
      Toxoplasmosis
      Trichomonas Vaginalis
      Tuberculosis
      Vibrio
      West Nile Virus
      Yersina
  2. Cancer Testing
    a. Overview
    b. Major Cancer Types
    Prostate
    Lung
    Colon and Rectum
    Breast
    Skin
    Uterine
    Leukemia
    Oral
    c. Oncogenes
      Abl/abl-bcr
      AIB1
      BCL-2
      BRCA1
      CD44
      C-fos
      C-myb
      C-myc
      CYP17
      Erb-B
      HPC1
      N-myc
      P40
      P51
      P53
      PIK3CA
      PTI-1
      Ras
      Reg
      Sis
      Src
  3. Genetic Diseases
    a. Overview
    b. Nucleic Acid Amplification
    c. Chromosome Imaging
    d. Genomics Technologies
    e. Proteomics Technologies
    f. Current Pharmacogenomic Tests
    g. Future Pharmacogenomic Testing
    h. Major Diseases
    Achondroplasia
    Autosomal Dominant Polycystic Kidney Disease
    Cancer
    Cosmetogenomics
    Cystic Fibrosis
    Down's Syndrome
    Duchenne and Becker Muscular Dystrophy
    Factor V (Leiden)
    Factor IX Deficiency
    Fragile X Syndrome
    Heart Disease
    Hemochomatosis
    Hemophilia
    Huntington's Disease
    Maternal-Fetal Incompatibility
    Multiple Endocrine Neoplasia
    Phenylketonuria (PKU)
    Polycystic Kidney Disease (PKD)
    Prenatal Screening
    Retinitis Pigmentosa
    Retinoblastoma
    Sickle Cell Anemia
    Spinal Muscular Atrophy
    Vitamin B12 Metabolism
    i. Social Issues and Concerns
  4. Forensic Testing
    a. Overview
    b. Multilocus and Single Locus Probes
    Multilocus Probes
    Single Locus Probes
    PCR and RFLP
    c. The FBI
    d. DNA Profile Data Banks
    U.S.A.
    U.K.
    e. Judicial Implementation
    f. Major Crime Categories
    g. Factors Contributing to the DNA Probe Market Expansion
    Technology Availability
    Use of Hair as Evidence
    h. Wildlife Forensics
  5. Paternity Testing/HLA Typing
  6. Other Applications
    a. Disease Susceptibility Testing
    b. Cardiovascular Diseases
    c. Diabetes
    d. Alzheimer's Disease
    e. Periodontal Disease
    f. Plasma Purification
    g. Organ Transplantation
    h. Water Contamination
    i. Other
H. Competing/complementing
  1. Monoclonal Antibodies/Immunoassays
  2. RNA Probes
  3. Two-Dimensional Electrophoresis
  4. Flow Cytometry

VII. U.S.A. MOLECULAR DIAGNOSTICS MARKET

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts, Major Supplier Sales and Market Shares

VIII. COMPETITIVE ASSESSMENTS

Abbott
Affymetrix
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Biotest
Cepheid
CellMark Forensics/LabCorp
Decode Genetics
Diadexus
Eiken
Elitech Group
Enzo

LIST OF TABLES

Major Companies Developing or Marketing AIDS Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Adenovirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Campylobacter Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Candida Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Chlamydia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Cryptosporidium Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing CMV Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing EBV Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Helicobacter Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Hepatitis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Herpes Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Influenza Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Legionella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Malaria Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Measles Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Meningitis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Mononucleosis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Mumps Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Pneumonia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing RSV Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Rotavirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Rubella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Salmonella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Septicemia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Shigella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Streptococci Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Syphilis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Trichomonas Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic and Other Direct Identification Tests
Oncogenes Potential Application in Cancer Diagnosis
Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests
Major Companies Developing or Marketing Molecular Diagnostic Tests For Genetic Diseases
U.S.A.
Molecular Diagnostics Test Volume And Sales By Major Application
U.S.A.
Laboratories Performing DNA Sequencing By Market Segment


More Publications